Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series
BackgroundRheumatic mitral stenosis (RMS) is a common valvular heart disease in developing countries. We sought to evaluate the early experience of patients with RMS undergoing transcatheter mitral valve replacement (TMVR).MethodsIn this retrospective study, a total of 5 RMS patients accepted TMVR....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1424105/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589604587307008 |
|---|---|
| author | Ping Jin Hong Guo Yu Mao Mengen Zhai Yang Liu Jian Yang |
| author_facet | Ping Jin Hong Guo Yu Mao Mengen Zhai Yang Liu Jian Yang |
| author_sort | Ping Jin |
| collection | DOAJ |
| description | BackgroundRheumatic mitral stenosis (RMS) is a common valvular heart disease in developing countries. We sought to evaluate the early experience of patients with RMS undergoing transcatheter mitral valve replacement (TMVR).MethodsIn this retrospective study, a total of 5 RMS patients accepted TMVR. All patients underwent computed tomography and echocardiography before having the procedure. After the preprocedural comprehensive evaluations, the surgeons planned to use the Prizvalve (a novel balloon-expandable transcatheter aortic valve system which is now under the clinical registration study) for TMVR. Clinical data were collected at baseline, before discharge, and at the 30-day follow-up.ResultsThe median age of the 5 RMS patients was 61 years (range 60–77 years); 60% were male, and the median Society of Thoracic Surgeons score was 13.3% (range 6.2–17.1%). TMVR was successful in all patients. Postoperative transesophageal echocardiography showed that 60.0% (n = 3) of the patients had no paravalvular leakage and 40.0% (n = 2) had trace paravalvular leakage. The median postoperative peak velocity decreased to 1.4 m/s (range 1.1–1.7 m/s), and the median pressure gradient decreased to 3 mmHg (range 2–3 mmHg). No deaths occurred at the 30-day follow-up, and all patients had an improvement of ≥1 on the New York Heart Association functional rating.ConclusionsOur early experience with TMVR in RMS patients suggests that it is a safe and feasible procedure. The early results of the procedure are acceptable and provide bright prospects and directions for the precision treatment of RMS.
Clinical Trial RegistrationClinicalTrials.gov, identifier (NCT02917980). |
| format | Article |
| id | doaj-art-fbc0b12e82b64902af0b16e8adf4301d |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-fbc0b12e82b64902af0b16e8adf4301d2025-01-24T12:30:07ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2024-12-011110.3389/fcvm.2024.14241051424105Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case seriesPing JinHong GuoYu MaoMengen ZhaiYang LiuJian YangBackgroundRheumatic mitral stenosis (RMS) is a common valvular heart disease in developing countries. We sought to evaluate the early experience of patients with RMS undergoing transcatheter mitral valve replacement (TMVR).MethodsIn this retrospective study, a total of 5 RMS patients accepted TMVR. All patients underwent computed tomography and echocardiography before having the procedure. After the preprocedural comprehensive evaluations, the surgeons planned to use the Prizvalve (a novel balloon-expandable transcatheter aortic valve system which is now under the clinical registration study) for TMVR. Clinical data were collected at baseline, before discharge, and at the 30-day follow-up.ResultsThe median age of the 5 RMS patients was 61 years (range 60–77 years); 60% were male, and the median Society of Thoracic Surgeons score was 13.3% (range 6.2–17.1%). TMVR was successful in all patients. Postoperative transesophageal echocardiography showed that 60.0% (n = 3) of the patients had no paravalvular leakage and 40.0% (n = 2) had trace paravalvular leakage. The median postoperative peak velocity decreased to 1.4 m/s (range 1.1–1.7 m/s), and the median pressure gradient decreased to 3 mmHg (range 2–3 mmHg). No deaths occurred at the 30-day follow-up, and all patients had an improvement of ≥1 on the New York Heart Association functional rating.ConclusionsOur early experience with TMVR in RMS patients suggests that it is a safe and feasible procedure. The early results of the procedure are acceptable and provide bright prospects and directions for the precision treatment of RMS. Clinical Trial RegistrationClinicalTrials.gov, identifier (NCT02917980).https://www.frontiersin.org/articles/10.3389/fcvm.2024.1424105/fullmitral stenosisrheumatic valvular heart diseasetranscatheter mitral valve replacementprizvalvemitral valve |
| spellingShingle | Ping Jin Hong Guo Yu Mao Mengen Zhai Yang Liu Jian Yang Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series Frontiers in Cardiovascular Medicine mitral stenosis rheumatic valvular heart disease transcatheter mitral valve replacement prizvalve mitral valve |
| title | Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series |
| title_full | Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series |
| title_fullStr | Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series |
| title_full_unstemmed | Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series |
| title_short | Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series |
| title_sort | transcatheter mitral valve replacement to treat rheumatic mitral stenosis a case series |
| topic | mitral stenosis rheumatic valvular heart disease transcatheter mitral valve replacement prizvalve mitral valve |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1424105/full |
| work_keys_str_mv | AT pingjin transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries AT hongguo transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries AT yumao transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries AT mengenzhai transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries AT yangliu transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries AT jianyang transcathetermitralvalvereplacementtotreatrheumaticmitralstenosisacaseseries |